BiogenBIIB
Market Cap: $29.2B
About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Employees: 7,570
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
38% more funds holding in top 10
Funds holding in top 10: 8 [Q1] → 11 (+3) [Q2]
7% more capital invested
Capital invested by funds: $27.8B [Q1] → $29.7B (+$1.88B) [Q2]
0.72% less ownership
Funds ownership: 88.7% [Q1] → 87.98% (-0.72%) [Q2]
6% less repeat investments, than reductions
Existing positions increased: 311 | Existing positions reduced: 330
1% less funds holding
Funds holding: 925 [Q1] → 914 (-11) [Q2]
10% less first-time investments, than exits
New positions opened: 99 | Existing positions closed: 110
11% less call options, than puts
Call options by funds: $314M | Put options by funds: $353M
Research analyst outlook
17 Wall Street Analysts provided 1 year price targets over the past 3 months
17 analyst ratings
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target | 42%upside $285 | Buy Reiterated | 4 Sept 2024 |
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target | 42%upside $285 | Buy Reiterated | 19 Aug 2024 |
Mizuho Salim Syed 44% 1-year accuracy 8 / 18 met price target | 25%upside $251 | Outperform Maintained | 6 Aug 2024 |
Truist Securities Srikripa Devarakonda 67% 1-year accuracy 14 / 21 met price target | 50%upside $302 | Buy Reiterated | 5 Aug 2024 |
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target | 42%upside $285 | Buy Maintained | 5 Aug 2024 |
Financial journalist opinion
Based on 10 articles about BIIB published over the past 30 days